Fluticasone propionate/formoterol: A fixed-combination therapy with flexible dosage

Nicola Scichilone, Pierluigi Paggiaro, Andrea Rossi, Cazzola, Giorgio Walter Canonica, Andrea S. Melani, Blasi, Maria Pia Foschino Foschino Barbaro, Centanni, Fabio L.M. Ricciardolo, Alberto Papi

Risultato della ricerca: Article

6 Citazioni (Scopus)

Abstract

International guidelines describe asthma control as the main outcome of asthma management. Prevention of symptoms, improved quality of life, and reduction of exacerbations are the main components, consequently decreasing health care costs. However, many of these objectives remain unmet in real life: several surveys show that a large proportion of asthmatic patients are not well controlled despite the efficacy of current available treatment. Several randomized controlled clinical trials indicate that combining inhaled corticosteroids and long-acting β2-agonists, by means of a single inhaler, greatly improves the management of the disease. The results of 9 multicenter phase III clinical studies demonstrate that the fixed combination of fluticasone propionate/formoterol in a single inhaler is effective in terms of lung function and symptom control. These studies highlight the dose flexibility, safety and tolerability of this new inhaled combination. These characteristics meet the recommendations of international guidelines, and the preferences of respiratory physicians who identified these aspects as critical components of a successful asthma therapy. Combination of fluticasone propionate/formoterol in a single inhaler provides potent anti-inflammatory activity of fluticasone propionate and rapid onset of action of the β2-agonist formoterol making this association a viable treatment option both in terms of effectiveness and compliance.
Lingua originaleEnglish
Numero di pagine9
RivistaEuropean Journal of Internal Medicine
Volume19
Stato di pubblicazionePublished - 2014

Fingerprint

Nebulizers and Vaporizers
Asthma
Guidelines
Disease Management
Health Care Costs
Compliance
Adrenal Cortex Hormones
Anti-Inflammatory Agents
Therapeutics
Randomized Controlled Trials
Quality of Life
Physicians
Safety
Lung
Fluticasone
flutiform

All Science Journal Classification (ASJC) codes

  • Internal Medicine

Cita questo

Scichilone, N., Paggiaro, P., Rossi, A., Cazzola, Canonica, G. W., Melani, A. S., ... Papi, A. (2014). Fluticasone propionate/formoterol: A fixed-combination therapy with flexible dosage. European Journal of Internal Medicine, 19.

Fluticasone propionate/formoterol: A fixed-combination therapy with flexible dosage. / Scichilone, Nicola; Paggiaro, Pierluigi; Rossi, Andrea; Cazzola; Canonica, Giorgio Walter; Melani, Andrea S.; Blasi; Foschino Barbaro, Maria Pia Foschino; Centanni; Ricciardolo, Fabio L.M.; Papi, Alberto.

In: European Journal of Internal Medicine, Vol. 19, 2014.

Risultato della ricerca: Article

Scichilone, N, Paggiaro, P, Rossi, A, Cazzola, Canonica, GW, Melani, AS, Blasi, Foschino Barbaro, MPF, Centanni, Ricciardolo, FLM & Papi, A 2014, 'Fluticasone propionate/formoterol: A fixed-combination therapy with flexible dosage', European Journal of Internal Medicine, vol. 19.
Scichilone, Nicola ; Paggiaro, Pierluigi ; Rossi, Andrea ; Cazzola ; Canonica, Giorgio Walter ; Melani, Andrea S. ; Blasi ; Foschino Barbaro, Maria Pia Foschino ; Centanni ; Ricciardolo, Fabio L.M. ; Papi, Alberto. / Fluticasone propionate/formoterol: A fixed-combination therapy with flexible dosage. In: European Journal of Internal Medicine. 2014 ; Vol. 19.
@article{1e55bac9cbcf49a0a7f10afe60000fa7,
title = "Fluticasone propionate/formoterol: A fixed-combination therapy with flexible dosage",
abstract = "International guidelines describe asthma control as the main outcome of asthma management. Prevention of symptoms, improved quality of life, and reduction of exacerbations are the main components, consequently decreasing health care costs. However, many of these objectives remain unmet in real life: several surveys show that a large proportion of asthmatic patients are not well controlled despite the efficacy of current available treatment. Several randomized controlled clinical trials indicate that combining inhaled corticosteroids and long-acting β2-agonists, by means of a single inhaler, greatly improves the management of the disease. The results of 9 multicenter phase III clinical studies demonstrate that the fixed combination of fluticasone propionate/formoterol in a single inhaler is effective in terms of lung function and symptom control. These studies highlight the dose flexibility, safety and tolerability of this new inhaled combination. These characteristics meet the recommendations of international guidelines, and the preferences of respiratory physicians who identified these aspects as critical components of a successful asthma therapy. Combination of fluticasone propionate/formoterol in a single inhaler provides potent anti-inflammatory activity of fluticasone propionate and rapid onset of action of the β2-agonist formoterol making this association a viable treatment option both in terms of effectiveness and compliance.",
author = "Nicola Scichilone and Pierluigi Paggiaro and Andrea Rossi and Cazzola and Canonica, {Giorgio Walter} and Melani, {Andrea S.} and Blasi and {Foschino Barbaro}, {Maria Pia Foschino} and Centanni and Ricciardolo, {Fabio L.M.} and Alberto Papi",
year = "2014",
language = "English",
volume = "19",
journal = "European Journal of Internal Medicine",
issn = "0953-6205",
publisher = "Elsevier",

}

TY - JOUR

T1 - Fluticasone propionate/formoterol: A fixed-combination therapy with flexible dosage

AU - Scichilone, Nicola

AU - Paggiaro, Pierluigi

AU - Rossi, Andrea

AU - Cazzola, null

AU - Canonica, Giorgio Walter

AU - Melani, Andrea S.

AU - Blasi, null

AU - Foschino Barbaro, Maria Pia Foschino

AU - Centanni, null

AU - Ricciardolo, Fabio L.M.

AU - Papi, Alberto

PY - 2014

Y1 - 2014

N2 - International guidelines describe asthma control as the main outcome of asthma management. Prevention of symptoms, improved quality of life, and reduction of exacerbations are the main components, consequently decreasing health care costs. However, many of these objectives remain unmet in real life: several surveys show that a large proportion of asthmatic patients are not well controlled despite the efficacy of current available treatment. Several randomized controlled clinical trials indicate that combining inhaled corticosteroids and long-acting β2-agonists, by means of a single inhaler, greatly improves the management of the disease. The results of 9 multicenter phase III clinical studies demonstrate that the fixed combination of fluticasone propionate/formoterol in a single inhaler is effective in terms of lung function and symptom control. These studies highlight the dose flexibility, safety and tolerability of this new inhaled combination. These characteristics meet the recommendations of international guidelines, and the preferences of respiratory physicians who identified these aspects as critical components of a successful asthma therapy. Combination of fluticasone propionate/formoterol in a single inhaler provides potent anti-inflammatory activity of fluticasone propionate and rapid onset of action of the β2-agonist formoterol making this association a viable treatment option both in terms of effectiveness and compliance.

AB - International guidelines describe asthma control as the main outcome of asthma management. Prevention of symptoms, improved quality of life, and reduction of exacerbations are the main components, consequently decreasing health care costs. However, many of these objectives remain unmet in real life: several surveys show that a large proportion of asthmatic patients are not well controlled despite the efficacy of current available treatment. Several randomized controlled clinical trials indicate that combining inhaled corticosteroids and long-acting β2-agonists, by means of a single inhaler, greatly improves the management of the disease. The results of 9 multicenter phase III clinical studies demonstrate that the fixed combination of fluticasone propionate/formoterol in a single inhaler is effective in terms of lung function and symptom control. These studies highlight the dose flexibility, safety and tolerability of this new inhaled combination. These characteristics meet the recommendations of international guidelines, and the preferences of respiratory physicians who identified these aspects as critical components of a successful asthma therapy. Combination of fluticasone propionate/formoterol in a single inhaler provides potent anti-inflammatory activity of fluticasone propionate and rapid onset of action of the β2-agonist formoterol making this association a viable treatment option both in terms of effectiveness and compliance.

UR - http://hdl.handle.net/10447/100408

M3 - Article

VL - 19

JO - European Journal of Internal Medicine

JF - European Journal of Internal Medicine

SN - 0953-6205

ER -